Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of drugmaker KV Pharmaceutical
So what: KV was one of last week's biggest losers after receiving political scrutiny for jacking up the price of its preventive preterm birth treatment, Makena, so a big double-digit bounce shouldn't come as a huge surprise. With a beta of three and so much controversy surrounding KV's alleged price gouging tactics, the stock is rapidly becoming an active trader's dream situation.
Now what: KV shares aren't for the faint of heart. While Makena's whopping profit potential has fueled the stock to great heights, it's tough not to notice the ever-increasing outrage toward KV from patients, doctors, and now politicians. As the situation plays itself out and sentiment sways back and forth, investors can expect plenty more opportunities -- be it long or short -- to arise.
Interested in more info on KV? Add it to your watchlist.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.
More from The Motley Fool
The Dow's Run Is Not Done
The Dow submits its second down week of 2012.
These 5 Companies Have Dominated 2012
The first three weeks of the year have been very good to shareholders in these five companies.
2012 Preview: K-V Pharmaceuticals
Here's what the new year has in store for K-V Pharmaceuticals.